51. Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: bridging molecular studies and clinical trials
- Author
-
C.P. Simon, Víctor Fernández-Dueñas, Francisco Ciruela, Josep Maria Arnau, M.A. Quijada, Gloria García-Negredo, Silvia Sánchez, Maria Laura Cuffí, Antoni Vallano, Lourdes Carbonell, and Universitat de Barcelona
- Subjects
Parkinson's disease ,Receptor, Metabotropic Glutamate 5 ,Receptors de neurotransmissors ,Neurotransmission ,Antiparkinson Agents ,Neurotransmitter receptors ,Glutamatergic ,Therapeutic approach ,Drug Delivery Systems ,Neuropharmacology ,Clinical trials ,Malaltia de Parkinson ,medicine ,Animals ,Humans ,Receptor ,Pharmacology ,Clinical Trials as Topic ,General Neuroscience ,Glutamate receptor ,Parkinson Disease ,medicine.disease ,Corpus Striatum ,Metabotropic receptor ,Metabotropic glutamate receptor ,Psychology ,Neuroscience ,Neurofarmacologia ,Assaigs clínics - Abstract
Metabotropic glutamate (mGlu) receptors are G protein-coupled receptors expressed primarily on neurons and glial cells modulating the effects of glutamatergic neurotransmission. The pharmacological manipulation of these receptors has been postulated to be valuable in the management of some neurological disorders. Accordingly, the targeting of mGlu 5 receptors as a therapeutic approach for Parkinson’s disease (PD) has been proposed, especially to manage the adverse symptoms associated to chronic treatment with classical PD drugs. Thus, the specific pharmacological blocking of mGlu 5 receptors constitutes one of the most attractive non-dopaminergic-based strategies for PD management in general and for the L-DOPA-induced diskynesia (LID) in particular. Overall, we provide here an update of the current state of the art of these mGlu 5 receptor-based approaches that are under clinical study as agents devoted to alleviate PD symptoms.